The inhibition of the ERK1/2-Dynamin-related protein 1 (Drp1)–ROS axis was recently suggested as a potential therapeutic strategy to rescue RGC loss and counteract pathologically high intraocular pressure, a primary risk factor for glaucoma [20]. Here, DNM1L is linked to glaucoma.